Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Latest Proposal to Discuss Reference Pricing System Gets Cold Shoulder from CSIMC
September 26, 2012
- MHLW Reports 1 Dispensing Error Due to Name Similarity; Almarl Already Renamed
September 24, 2012
- MHLW Issues Notification to Prohibit Dispensing Point Services
September 21, 2012
- MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
- Reimbursement of Generic Drugs Used Off-Label “Not Necessarily Illegal,” Government Says
September 20, 2012
- Half of Hospitals Participating in Network Play Central Role: MHLW FY2011 Survey
September 19, 2012
- MHLW Eyes Introduction of Piecework Payment for Clinical Trials at 54 Hospitals by FY2016
September 18, 2012
- MHLW Budget Request Includes Funds for Database of Information on Patients with Cancer, Lifestyle Diseases
September 18, 2012
- MHLW Calls for Self-Inspections at Japanese Pharmaceutical Firms after “Gutter Oil”-Made Antibiotic Intermediates Found in China
September 14, 2012
- MHLW Instructs Daiichi Sankyo to Issue Blue Letter on Ranmark Following Two Reported Deaths
September 13, 2012
- MEXT Calls for 21 Billion Yen for Special Priority Area of Healthcare Innovation in FY2013 Budget Request
September 12, 2012
- Osaka District Court to Issue Ruling on Actos Patent Suit on Sept. 27
September 12, 2012
- MHLW Issues Q&As on Drug Risk Management Plans to Prefectures
September 12, 2012
- MHLW Notifies of Expected Additional Indications for 3 APIs
September 12, 2012
- PAFSC’s 2nd Committee Designates 7 products as Orphan Drugs Including Glioblastoma Treatment Bevacizumab
September 11, 2012
- Chairman Breaks Tie, Votes to Continue Lower House Discussions on Bill to Establish 3rd-Party Organization
September 11, 2012
- MHLW’s FY2013 Budget Request Includes Funding to Set Up Municipal Generic Drug Promotion Councils
September 11, 2012
- PAFSC 2nd Committee Recommends Approval for Novartis’s COPD Drug
September 11, 2012
- DPJ’s Project Team Concerned that Participation in TPP Agreement Could Interfere with Japan’s Industrial Policies
September 10, 2012
- MHLW to Study Overseas Generic Drug Markets to Support Globalization of Domestic Industry
September 10, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…